Clinical Trials Logo

Clinical Trial Summary

A feasibility study to evaluate the usability of the REVEAL 475 system in patients treated with bevonescein for nerve visualization during surgery.


Clinical Trial Description

The REVEAL 475 system will be evaluated for its ability to visualize nerve-fluorescence following bevonescein administration. All patients will receive a single dose of bevonescein 500 mg via IV infusion 1-5 hours before undergoing parotidectomy, thyroidectomy or neck dissection surgery. ;


Study Design


NCT number NCT06227585
Study type Interventional
Source Alume Biosciences, Inc.
Contact Brett Berman, MD
Phone 858-922-3977
Email brett.berman@alumebiosciences.com
Status Recruiting
Phase Phase 2
Start date November 29, 2023
Completion date June 2024